What went wrong? We had 20.5% mortality for leronlimab. Based on EINDs I figured we'd get 17% to 20% so not much off there. Where things go awry is in the 21.6% percent in the placebo. A bit of that would be accountable from improved SOC, quite a bit of that could be accountable from the skew in 65+ year old patients.